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ABSTRACT 
 
Recent medical advances and the rising prevalence of chronic pain in the US 
population contribute to the use of spinal cord stimulator (SCS) implant as a treatment 
modality for chronic pain management. As the numbers of patients receiving SCS 
implants steadily increases, the challenge of managing this device grows and the need for 
SCS implants follow-up programs rises. Follow-up programs need to focus on implant 
longevity and efficacy to improve the quality of care outcomes.   
This Doctor of Nursing Practice (DNP) quality improvement initiative was 
developed to provide systematic follow-up for patient with SCS implant. The project 
includes the creation of a database for all of the SCS implants currently managed by this 
medical center; development and administration of the questionnaire to improve the 
effectiveness of this modality; development of a multidisciplinary team, including the 
representatives of the device manufacturers, to improve device management; and 
maintenance of the treatment space to assure timely access by appointment.  
Data were collected via a questionnaire, administered to 80 patients as part of the 
follow-up program. Analysis of the data yielded these patient outcomes: 33 (41.25% of 
respondents) had satisfactory pain coverage requiring no further intervention; 27 
(33.75%) needed SCS device reprogramming; 7 (8.7%) required surgical intervention for 
SCS implant management; 6 (7.5%) needed interventions but were not ready to receive 
the intervention; and 7 (8.75%) patients requested additional procedure for pain 
management augmentation. 
Post hoc comparisons using the Bonferroni adjustment for Type I error rate 
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inflation showed that patients who reported a remodulation time of less than 6 months (M 
= 4.97, SD = 2.35) reported significantly less pain than patients who reported a 
remodulation time between 6 and 12 months (M = 5.65, SD = 2.16) and more than 12 
months (M = 5.86, SD = 2.66). The pairwise comparison between patients who reported 
remodulation time between 6 and 12 months and more than 12 months was not 
significant, p > .05. Thus, the greater the time since remodulation of SCS implant, the 
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CHAPTER 1 
INTRODUCTION 
A QUALITY IMPROVEMENT INITIATIVE: SYSTEMATIC FOLLOW-
UP OF PATIENTS WHO HAVE SPINAL CORD STIMULATOR 
IMPLANTS 
 The Institute of Medicine (2011) released a report stating that more than 110 
million Americans suffer from chronic pain and that the cost totals $635 billion each year 
in medical treatment and loss of productivity; however, the emotional burden for those 
afflicted by chronic pain and for the whole society is impossible to calculate. Chronic 
pain results in depression, poor quality of life, and ultimately loss of livelihood. Chronic 
pain is a major driving force for a patient to seek medical attention (Kumar, Wilson, & 
Taylor, 2006; North, Kidd, Farrokhi, & Piantadosi, 2005; North & Shipley, 2007). The 
spinal cord stimulator (SCS) implant was first implemented by Shealy et al. in 1967 as a 
treatment modality for chronic pain management. Since then it has been used with 
increasing success for management of Failed Back Surgery Syndrome (FBSS), chronic 
regional pain syndrome (CRPS), peripheral vascular disease, refractory angina, and pain 
secondary to multiple sclerosis (Horsch, Schulte, & Hess, 2004; North et al., 2005). An 
increasing body of clinical evidence illustrates the effective use of this modality for the 
treatment of pain from post-herpetic neuralgia, peripheral neuropathy, occipital neuralgia, 
and other neuropathic conditions. Further clinical evidence illustrates that 
neurostimulation is effective in treating ischemic pain produced by cardiovascular and 
peripheral vascular diseases, along with interstitial cystitis pain (Atkinson, Sundaraj, 
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Brooker, O’Callaghan, Teddy, Salmon, . . . Majedi, 2011; Mekhail, Cheng, Narouze, 
Kapural, Mekhail, & Deer, 2010; North et al., 2007). 
Mekhail et al. (2010) noted that 50,000 neurostimulators are implanted worldwide 
each year for the treatment of a variety of painful conditions, and total sales of SCS 
implants are predicted to rise. When all traditional interventions have failed, the SCS is 
considered one of the most effective modalities for chronic pain management (Atkinson 
et al., 2011; Mekhail et al., 2010).  North and Shipley (2007) outlined the potential 
beneficial outcomes associated with the SCS implant placement, such as significant pain 
relief and improvement quality of life, reduction of consumption of health care resources, 
improvement in ability to engage in the activities of daily living and return to work, 
patient satisfaction with treatment, and improvement in symptoms of depression and 
neurological function. Atkinson et al., (2011) asserted that unlike surgical pain relief 
procedures the placement of the specific types of SCS implants does not change the 
anatomy or ablate pain pathways, which makes it completely reversible. The United 
States (U.S.) Food and Drug Administration currently approved the use of SCS implant 
therapy for chronic pain of the trunk and limbs, FBSS, and intractable low back pain 
(LBP) (Compton, Shah, & Hayek, 2012). As the U.S. population ages, there is a growing 
population suffering from neurodegenerative diseases such as Parkinson’s, incontinence, 
chronic pain, and other conditions that create an opportunity for neurostimulation use and 
increase of use of this treatment modality (Krames, Peckham, & Rezai, 2009). 
           Despite multiple benefits and applications of SCS implant as treatment modality 
Turner and colleagues (2004) reported in their comprehensive meta-analysis of 22 studies 
that complications of any sort occurred in 34.3% cases. Hardware complications included 
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equipment failure (10.2%), required surgical stimulator revision other than battery change 
(23.1%), or stimulator removal (11.0%).  Biological complications included superficial 
infection (4.5%), deep infection (0.1%), pain in the region of stimulator components 
(5.8%), and complications other than infection or local pain (2.5%).  
It should be also noted that this treatment modality is not long term; the pain-
alleviating effect of the SCS implant in complex regional pain syndrome patients 
diminishes over time despite fully functional stimulating system (Kemler, De Vet, 
Barendse, Van Den Wildenberg, Van Kleef, 2008). Kumar and Wilson (2007), using 
their active database of 424 patients, examined causes of long term failures. They 
identified a group of 85 patients who, after an initial period of good pain relief, started to 
require increasing amplitude of current (SCS implant reprogramming) to maintain 
satisfactory pain control; the researchers labeled this as development of the “tolerance.” 
Since the effectiveness of this modality is constantly changing with a gradual decrease 
over time, the patient’s needs and satisfaction with the SCS implant therapy also change 
(Atkinson et al., 2011).   
The development of a systematic follow-up program for patient with SCS implant 
would help address patients’ needs in a timely manner, improve pain management, and 
provide ongoing assessment of malfunction and complications associated with the device; 
therefore, the creation of follow-up program would contribute to the longevity of SCS 
implant function and its efficacy. This project focuses on the development and 
implementation of the quality improvement initiative (QI) that encompasses the creation 
of systematic follow-up for patients with SCS implants. The QI initiative can bring 
expedited, focused changes into clinical practice by incorporating multilevel process with 
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a multidisciplinary approach, evidence-based practice, and individual innovations within 
the clinical area (Sollecito & Johnson, 2013). This QI initiative is designed and 
incorporated as part of the Anesthesia Pain Clinic’ s protocol. The clinic is within 
medical center that is part of Veterans Health Administration (VHA) located in western 
U.S. The goal of the QI project is aligned with the goal of the Anesthesia Pain Clinic: to 
provide continuity of care and the best possible outcomes for patients with chronic pain. 
Background and Significance 
The Veterans Health Administration (VHA) National Pain Management Strategy, 
initiated November 12, 1998, established pain management as a national priority with an 
objective to develop a comprehensive, multidisciplinary, integrated, system-wide 
approach to pain management. The intended outcome of this priority is to reduce pain 
and suffering while improving quality of life for veterans experiencing acute and chronic 
pain (VHA Directive 2009-053, 2009).  The VHA is a centrally administered, publicly 
supported entity that provides care to a defined population of veterans without concern 
for their ability to pay or preexisting health conditions (Feussner, Kizer, & Demakis, 
2000). Between 2000 to 2007, the incidence of chronic pain (including LBP) rose, and 
the number of individuals with a LBP diagnosis increased from 10,955 to 15,205 per 
100,000 VHA users at an annualized prevalence rate increase of 4.8% per year. This 
increasing prevalence of LBP is even more evident in reports among recently returning 
veterans (Gironda, Clark, Massengale, & Walker, 2006; Sinnott & Wagner, 2009). 
Due to increase in patients with pain of the VHA has implemented the “Pain as 
the 5th Vital Sign” initiative for all inpatient and outpatient clinical settings to ensure 
consistent recognition, the assessment of pain intensity, and the effects of pain on the 
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veteran’s function and quality of life.  The VHA asserts that an effective pain treatment 
plan must be developed and implemented, and the reassessment of the effectiveness of 
this plan must be completed and documented (VHA Directive 2009-053, 2009). Also the 
VHA National Pain Management Strategy Objectives 6 and 7 delineate the appropriate 
level and frequency of monitoring to improve the outcomes of pain management.  The 
use of an interdisciplinary, multimodal approach to pain management that emphasizes the 
optimal pain control and improved functionality and quality of life are important 
elements of this directive as well (VHA Directive 2009-053, 2009).    
VHA Directive 2009-053 (2009) emphasized the importance of non-
pharmacological interventions aimed toward optimal pain control and emphasized 
individualized patient care and pain medicine specialty procedures, such as injections, 
nerve blocks, and ablations including neuromodulation or SCS implants. Unfortunately, 
the SCS implant is a costly intervention; it is a labor intensive and invasive procedure, 
with possible complications and long-term problems that require the skills and judgments 
of specialists, involving lifetime management, adjustment, and follow up (Atkinson et al., 
2011; Hollingworth, Turner, Welton, Comstock, & Deyo, 2011). However, Simpson and 
colleagues (2009) concluded that the SCS implant is a cost effective modality when 
compared with alternative pain management techniques.  Evidence of the benefits of this 
treatment for conditions such as FBSS and CRPS supported this (Cameron, 2004; 
Compton, Shah, & Hayek, 2012). However, regular follow up visits are required in the 
first year following the implant to adjust stimulation parameters. In subsequent years, 
annual visits are necessary to assess the need for the modification of the pain 
management plan and to monitor the implantable pulse generator (IPG) battery life 
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(Atkinson et al., 201; North et, al., 2007). The SCS team should be available at all times, 
as problems or complications arise. For patients located a significant distance away from 
the SCS team need to handle travelling arrangements and follow up care (Atkinson et al., 
2011).  
In 2007, North and colleagues evaluated costs associated with the SCS implant, 
and when compared with reoperation for FBSS, the SCS provided significant savings for 
the patient, as well as for society ($48,357 for the SCS, compared to $105,928 for 
reoperation). This holds true even with the decline of effectiveness of the SCS implant 
over time, as demonstrated by Kemler, De Vet, Barendse, Van Den Wildenberg, and Van 
Kleef (2008). In their study they found that 95% of all patients who had received this 
intervention would still consider it even if the outcome were the same.   
This information and the VHA National Pain Management Strategy helped 
formulate the following two questions:  
1. What can be done to maximize the efficacy of the SCS implant for chronic 
pain management?  
2. Which steps or alterations in the management of this modality would 
produce significant and positive benefits for patients who are using this 
modality to achieve maximum pain relief?   
One way to determine the answers to these questions is the creation of a comprehensive 
follow-up program that would provide a systematic evaluation and timely interventions to 
for pain management and detection of early complications; the ability to effectively 
communicate this data to all healthcare providers; and engagement of a multidisciplinary 
team to manage patients with SCS implant using lessons learned from research and 
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evidence-based practice. The program would aim to provide uniform improvements 
across the organization for patients with SCS implant suffering from chronic pain. 
Purpose 
In recent years, the Veterans Health Administration (VHA) has required that 
research informs practice so that practice is guided by evidence-based medicine, clinical 
practice guidelines, reduction of unnecessary practice variations, and improvement of 
clinical information management systems (Feussner, Kizer, &Demakis, 2000).  The VHA 
Quality Enhancement Research Initiative (QUERI) focuses on translating research into 
clinical practice to improve patient outcomes at the systems level. As well the QUERI 
supports additional epidemiological, economic, and statistical expertise to practice 
decisions by increasing interactions among researchers, clinicians, management, and 
others involved in quality assessment and improvement (Feussner et al., 2000; Hayward, 
Hofer, Kerr, & Krein, 2004).   
The purpose of the development and implementation of this systematic follow-up 
QI initiative focused on patients who have SCS implants is to (a) create a database for all 
of the SCS implants currently managed by the Anesthesia Pain Clinic within the VHA 
medical center located in western part of U.S.; (b) develop a questionnaire to collect 
necessary information to guide the management of SCS implants and evaluate the 
effectiveness of the modality at 6 and 12 month intervals followed by a yearly follow 
ups; (c) create a multidisciplinary team (within the  Anesthesia Pain Clinic and 
Neurosurgery Department) with the integration of manufacturing representatives who 
will provide timely and effective reprogramming of the SCS device with the goal of 
achieving the best possible pain coverage for patients; and (d) maintenance of a physical 
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space where the reprogramming  and  management of the device will occur with 
appointments arranged and managed by the Anesthesia Pain Clinic. 
Policy Implications 
One implication of this QI initiative is the development a policy that requires the 
systematic follow-up of patients who have SCS implants. This will assure timely and 
appropriate assessments and access to care. Also research demonstrates that this would 
affect the longevity and the efficacy of SCS implant as the modality for chronic pain 
management. The questionnaire administered within this QI project uncovers the areas 
needed for the follow-up intervention and provides area for ongoing communication 
within the members of the multidisciplinary team. The QI initiative also addresses the 
need for access to additional space for patient education and the reprogramming of 
devices. The positive evaluation of the interventions provided during this QI project 
along with multiple patients request for follow up led to the approval and development of 
the Neuromodulation Clinic that is now part of Anesthesia Pain Clinic. The new 
Neuromodulation Clinic is now open every Monday to accommodate the pre-scheduled 
appointments for patients with SCS implants who need or require additional interventions 
or education. As an additional benefit part of this QI initiative, manufacturing 
representatives from St. Jude company agreed to provide a comprehensive one hour 
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CHAPTER 2 
REVIEW OF THE LITERATURE 
            A search of literature focusing on SCS implant modality was undertaken through 
a computerized database search of Medline, Cochrane, and the UNLV library using 
search terms, such as spinal cord stimulation, chronic pain, failed back surgery syndrome, 
chronic regional pain syndrome, neuromodulation, Veteran Health Administration, 
quality improvement and quality improvement in Quality Enhancement Research 
Initiative, follow up systems, multidisciplinary team, and Kotter’s Change Theory. 
Theories Related to the SCS Implant for Pain Management 
          The gate theory presented by Melzack and Wall (1965) laid the foundation for 
understanding the mechanism of pain production and pain reduction by balancing the 
input between the large and small fibers in the spinal cord. The concepts of gate theory 
were placed in practice by Shealy et al., (1967) when they developed the concept of SCS 
implant and performed the first placement of stimulated electrodes. However the gate 
theory does not fully explain the mechanism of SCS pain control, as stimulation does 
more than directly inhibit pain transmission (Kumar & Wilson, 2007). Today, the 
biopsychosocial (BSP) model of chronic pain first proposed by George Engel is the most 
appropriate conceptual framework for understanding the clinical course of persistent pain 
and for organizing treatment (Gallagher & Verma, 2004). The BSP model incorporates 
the fluidity of how physical, psychological, social factors affect pain perception, 
neurophysiology of nociception, pain modulation, patients’ personal suffering, and their 
behavior (Borrell-Carrio, Suchman, & Epstein, 2004). In this model patients’ pain level, 
their responses to treatment, and their disability levels are affected by a factors such as 
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attitude, beliefs, expectations, mood, and social support system and the status of their 
compensation case (Gallagher & Verma, 2004). The BPS model is both a philosophy of 
clinical care and a practical clinical guide, as it provides a way of understanding how 
suffering, disease, and illness are affected by multiple levels of organization, from the 
societal to the molecular.  It opens the possibility of understanding the patient’s subjective 
experience as an essential contributor towards accurate diagnosis, health outcomes, and 
humane care. This model also allows for the incorporation of a psychological evaluation 
as a significant part of the criteria necessary for the successful long-term management of 
pain with the SCS implant placement (Gallagher & Verma, 2004; VHA Directive 2009-
053, 2009). 
Mechanism of Action and Evidence Related to the SCS Implant for Pain 
Management 
An SCS implant placed into the epidural space is able to produce and transmit an 
electrical current to the dorsal column, creating a tingling sensation in the corresponding 
dermatomes, although the mechanism of this action is not completely understood. The 
SCS implant produces non-painful paresthesia in areas where pain is located (Falowski, 
Celii, & Sharan, 2008). Two different mechanisms of action are accepted today: the relief 
of neuropathic pain produced by the suppression of hyper-excitability of dorsal horn 
neurons and the relief of ischemic states/pain produced by restoring the oxygen 
demand/supply by the inhibition sympathetic system (Kunnumpurath, Srinivasagopalan, 
& Vadivelu, 2009). The SCS system consists of a generator with controls, conductive 
leads, and implanted stimulating electrodes. Although SCS implant commonly described 
as “totally implanted” the system still requires external equipment to control stimulation 
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parameters (Kumar & Wilson, 2007). The patients have a small portable control unit 
available to make simple adjustments, and larger system adjustments are made by the 
manufacturing representatives or physicians (Krames, 2006; North, Khalessi, Calkins, 
Piantadosi, Campbell, Daly,…Taylor, 2004). 
            The internally powered, implanted pulse generator (IPG) has been used for more 
than 20 years, and it has its own battery that needs to be replaced periodically (Kumar, 
Wilson, Taylor, Gupta , 2006). When battery is depleted the IPG requires a surgical 
replacement, incurring additional risk and cost. It should be noted that IPG life is 
determined by the programmed settings of the SCS implant, thus making effective 
reprogramming and remodulation of the SCS implant a valuable option for the extending 
the longevity of IPG (North et al., 2004; Atkinson et al., 2011).  As of 2006, the number 
of companies manufacturing devices for the treatment of pain has increased from one 
major company, Medtronic, Inc., to five major companies, including Medtronic, Inc.; 
Advanced Bionics, Inc. of Sylmar, California, a subsidiary of Boston Scientific 
Corporation; Advanced Neuromodulation Systems of Plano, Texas, a subsidiary of St. 
Jude Corporation of St. Paul, Minnesota; Cyberonics of Houston; and Codman, a Johnson 
and Johnson company (Krames, 2006). Various current, voltage, and waveform 
configurations are possible, and the effectiveness of the SCS implant can be optimized by 
adjusting stimulation parameters to prolong battery life by systematic reprogramming the 
device to provide better pain coverage and minimize the incidence of complications 
related to equipment design (Kunnumpurath, Srinivasagopalan, &Vadivelu, 2009). 
A randomized, controlled trial in the late 1990s with chronic, refractory CRPS 
pain patients supported the effectiveness of the SCS implant for treatment of chronic pain 
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(Kemler et al., 2004).  These patients were evaluated at yearly intervals for up to five 
years.  A variety of measures, such as the visual analog scale (VAS), McGill Pain 
Questionnaire, the global perceived effect (7-point scale), and the quality of life profile 
(Sickness Impact Profile and Nottingham Health Profile) were used to evaluate the 
effectiveness of treatment related to pain.  At two years, the SCS group continued to have 
a significant (P < 0.001) mean decrease in the VAS of 2.1 cm, compared to 0.0 cm for the 
physical therapy (PT) treatment alone group.  Furthermore, 43% of those in the SCS 
group continued to rate themselves as “much improved” compared with only 6% in the 
PT-alone group (Kemler et al., 2004). 
 SCS implantation is considered most effective for the pain of neuropathic origins, 
such as in FBSS and CRPS (Atkinson et al., 2011; North & Shipley, 2007).  The SCS 
modality is often considered the last resort for persistent or recurrent pain after 
lumbarsacral spine surgery, which is often associated with nerve root compression and is 
treated by repeated operations or by the SCS implant (North et al., 2005).  Harke, 
Gretenkort, Ladleif, and Rahman (2005) completed a prospective study on 29 patients 
with type I CRPS. Their study illustrated the importance of the SCS implant for chronic 
pain management and its positive impact on patient’s quality of life.  These patients’ pain 
was not relieved by pain medication and PT and they had only a temporary positive 
response to a sympathetic block.  All patients in the study had an implantation with the 
SCS system, and a 12-month follow-up revealed that deep pain had decreased from a 
mean of 10 cm to 1.7 cm and allodynia (pain due to a stimulus which does not normally 
provoke pain) had been essentially resolved (P < 0.01).  In a patient follow-up roughly 
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three years later, deep pain remained at a mean of 2 cm on the VAS scale, and 70% of 
these patients had returned to work (Harke et al., 2005). 
 The SCS implant is more effective than reoperation for FBSS, and it significantly 
decreases the use of opiates. In 2005, North et al. performed a prospective, randomized 
study with 50 patients who were randomly assigned to receive SCS implants or 
reoperation for FBSS.  At a follow-up of about three years, 90% (45/50) of patients were 
evaluated. The SCS was significantly more successful in terms of pain control than 
reoperation; 47% of SCS patients versus 12% of reoperation patients reported 50% or 
greater pain relief (P < 0.01). The changes in work status and activities of daily living did 
not differ between the groups, but the group with the implantable SCS used significantly 
less narcotic analgesics (North et al., 2005). 
             Bannet and Brookoff (2006) pointed out that the SCS modality has a restorative 
effect that currently offers the best chance of obtaining long-term pain relief in CRPS 
patients, while it re-establishes and sustains blood flow to the affected area to preserve 
muscle and soft tissue.  Harke et al.’s (2005) study revealed that in a 12-month follow up 
after the placement of the SCS implant, all the patients had complete ablation of 
allodynia, 70% showed more than 50% reduction in the Pain Disability Index scoring, 
and 58.6% had stopped all medication. 
 Hollingworth, Turner, Welton, Comstock, and Deyo (2011) studied the cost-
effectiveness of the SCS implant for FBSS in a study that sampled of the worker’s 
compensation population.  They concluded that the mean medical cost per patient of the 
SCS implant over 24 months was $52,091.  This was $17,291 higher than in the pain 
clinic (PC) group and $28,128 higher than the usual care (UC) group.  The mean total 
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medical and productivity loss costs per patient of the SCS group were $20,074, which 
was higher than both the PC group and the UC group.  The study concluded that the SCS 
implant was highly unlikely to be the most cost-effective intervention.  It should be noted 
that this was a 24-month study; studies that were three years in duration supported an 
opposite view of the one accepted in current clinical practice. 
 SCS implantation has been proven cost effective in the longer term.  North et 
al.’s (2007) study examined the cost effectiveness in a follow-up of 42 patients for three 
years after their initial enrollment in a randomized controlled crossover trial evaluating 
SCS versus reoperation for FBSS.  The cost was $48,357 for SCS implanted patients, 
compared with $105,928 for patients who had a reoperation.  When treated with SCS 
therapy, patients generally required less follow-up care, which significantly decreased 
health care resource utilization and made SCS less expensive than conventional 
treatments over time (Mekhail et al., 2004).  North and Shipley (2007) noted that the 
cost-effectiveness of the SCS implant could be optimized by periodically adjusting 
stimulation parameters to prolong battery life, minimizing the incidence of complications, 
and improving equipment design and careful patient selection.     
 Patient selection is critical for successful long-term SCS implantation for 
chronic pain management (North, Kidd, Wimberley, & Edwin, 1996). Patients’ 
understanding of the procedure, realistic expectations of pain relief, and the ability to 
follow directions are critical and can be evaluated from interactions with the pain 
practitioner. With appropriate patient selection, neurostimulation is a valuable option to 
reduce pain, optimize function, improve the quality of life, and decrease health care costs 
in many of those suffering debilitating pain conditions.  The SCS implant does not 
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provide pain relief in all patients and is an expensive, labor intensive, invasive procedure 
with complications and ongoing management that requires specialists with specific skills 
and judgment (North, Kidd, Wimberley, & Edwin, 1996).  A multidisciplinary selection 
of appropriate patients for SCS is essential to achieving maximum benefit from the 
procedure (Doleys, 2006). 
 Currently, psychological testing has been conducted in an effort to identify 
predictors of success in SCS therapy.  Dumoulin, Devulder, Castille, De Laat, Van 
Bastelaere, and Rolly (1996) reported a correlation of greater than 0.8 on scores from a 
24-item questionnaire, and calculated an 80% accuracy rate using the Multiphasic 
Personality Inventory and Beck Depression Inventory and other tests.  Long and Webb 
(1980) also reported a 33% success rate in using SCS for chronic pain management in 
unscreened patients compared with 70% in screened patients.  Kumar, Toth, Nath, and 
Laing (1998) also found that patients considered appropriate for SCS therapy based on 
the results of psychological screening had better outcomes than those deemed 
inappropriate (North & Shipley, 2007). 
 Eighteen percent of SCS modalities fail due to lead migration, and it is the 
primary cause of a decrease in the effectiveness of SCS (Bannet & Brookoff, 2006).  
Lead migration is primarily due to falls or other accidents, and after the lead migration, it 
has been noted that there is a decrease of paresthesia coverage of the painful area.  In a 
review, Turner et al. (2004) found on average, 34% of patients had stimulator-related 
complications, and they also noted that the most common complication was electrode 
migration (11%).  Atkinson et al. (2011) pointed out that lead migration might occur at 
any time. Lead migration terminates or decreases the paresthesia in areas associated with 
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pain which leads to a lack of pain relief. It has been recommended that patients should 
not undertake activities that require excessive twisting or stretching during the first 3 
month after SCS implant (Atkinson et al., 2011).  Education about SCS implant therapy 
and PT are critical for reconditioning patients after the SCS implantation (North, 2007). 
 Careful follow up of patients with an implantable SCS device is necessary for 
successful long-term therapy.  Equipment-related problems can arise at any time after 
implantation, including discomfort at the IPG site, electrode breakage or migration, and 
infections. As a result, open dialog with patients is vital for the continued successful use 
of this modality (Falowski, Celii, & Sharan, 2008).  Cameron (2004) reported the 
following complication rates based on reviewed studies:  
1. Lead migration – 13.2% 
2. Lead breakage – 9.1% 
3. Infection – 3.4% 
4. Hardware malfunction – 2.9%   
5. Unwanted stimulation – 2.4%   
The most frequently seen issue is a loss of stimulation in the desired area due to 
lead migration and breakage, epidural fibrosis, or disease progression (Atkinson, 2011; 
North, 2006).  Diagnosis of these problems is made by plain films of a computer analysis 
of the impedance, a physical exam, and information obtained via the patient’s follow up 
interview/questionnaire. Reprogramming the device is the initial step in correcting these 
situations (Deer & Stewart, 2008).  
 In the application of SCS for chronic pain management, it is crucial to cover the 
patient’s painful areas with paresthesia, which results in a “tingling sensation.”  In order 
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to optimize this result, the SCS system must provide adequate neural selectivity; that is, 
maximal control over stimulation of the targeted nerves while avoiding stimulation of 
undesired neurons (Bradley, 2008).  Complex pain patterns require a high degree of 
flexibility in the implanted SCS system.  The medical team’s willingness and ability to 
provide extensive reprogramming in the long-term follow up is of utmost importance 
(Sharan, Cameron, & Barolat, 2002).  Brook, Gregory, and Olan (2009) pointed to issues 
with the SCS implant, such as a loss of stimulation due to wire fracture or battery 
depletion, stimulation of the wrong area due to lead migration, intermittent stimulation 
due to a lead in the wide epidural space, or painful stimulation.  All these issues require 
immediate attention. 
 It is critical to evaluate and document patient progress and the utility of the SCS 
implant for chronic pain management (Brook et al., 2009).  From the inception, and as 
the therapy progresses, pain scales, disability scores, and charts that detail location, 
duration, and degree of pain provide evidence of how effective the SCS implant is for 
pain management (Brook et al., 2009).  VASs are among the most commonly used 
measures of pain intensity in clinical and research settings, and the evidence supports the 
validity of this instrument to measure pain intensity in patients’ population (Ferreira-
Valente, Pais-Ribeiro, & Jensen, 2011). 
Needs Assessment 
            The current needs for the implementation of this QI program were identified using 
a comprehensive evaluation of current practices at the Anesthesia Pain Clinic and a 
review of practice recommendations based on research literature, evidence-based 
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practice, and input from Anesthesia Pain Clinic, Neurosurgery Department, medical 
records review, and patients’ requests.  
The evaluation included:  
Interviews. This study interviewed a number of health care providers to establish 
ways to improve care to the patients with SCS implant. Interviews were done with three 
members of the Anesthesia Pain Clinic, one representative from the Neurosurgery 
Department, two representatives from the device manufacturing companies, and three 
patients who came to the Pain Clinic for evaluation/reprogramming of their SCS device. 
The interviews revealed a need for current information about individual SCS device’s 
efficacy in relieving pain; a database of current patients with SCS implant who are 
managed by this facility; a comprehensive systematic follow-up of patient with SCS 
implants to improve device efficacy; development of effective communication between 
members of multidisciplinary team and manufacturing representatives; and creation of 
space to accommodate reprogramming of the device and necessary interventions. One of 
the representatives from the manufacturing company stated, “ VHA patients are very 
different from the patient that had the device implemented in a private practice. After the 
device was placed (in this population), they disappear, and do not stay in touch.”  The 
veterans population’s high prevalence of depression, homelessness, and post-traumatic 
stress disorder partly explain this disappearance (Rozanov & Carli, 2012). As well, and in 
some instances patients must drive more than 600 miles to get to this medical center. The 
interview with patients identified following issues: the effectiveness of the device 
decreased, but patients were not sure of how to follow-up on it; and they were not sure 
what changes in the modality would necessitate reprogramming of the device, contact 
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with the physician, which department to contact to report changes in SCS implant 
functions. 
Review of computerized patient record system (CPRS). The review of the CPRS 
information of five patients who received SCS implants revealed a lack of information 
about the effectiveness of the device for more than 2 weeks after implantation. There 
were also no systematic evaluations of the device’s effectiveness as well no protocol on 
documenting the changes in this treatment modality for chronic pain management. 
          These findings revealed the need for the comprehensive systematic follow-up 
system that incorporates adherence to the recommendations from latest research and 
evidence-based practice to improve management of chronic pain and maximize the 
efficacy of this modality. The development of this QI project incorporates systematic 
follow-up for patients with SCS implants and is aligned with the goals of the VHA 
system and the Anesthesia Pain Clinic. The goal of the project is to improve chronic pain 
management and provide quality care for patients. 
            According to the minimum requirements of the Australian Pain Society, pain 
services are responsible for ongoing care and follow up after the SCS implant has been 
placed (Atkinson et al., 2011).  Postoperative support—including physical rehabilitation, 
psychological support, medication adjustment, SCS system programming and 
management of any complications, and the eventual replacement of non-rechargeable 
IPG systems—is required (Atkinson et al, 2011).  The VA Anesthesia Pain Clinic 
evaluation revealed the need for a comprehensive follow-up program that would reflect 
the latest research and evidence data, comply with the VHA directives, actively respond 
to patient requests and needs, and be at forefront of safety and quality of care delivered to 
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veterans. Having an active data base of these patients and placing this information into 
CPRS is critical for the systematic follow-up program. 
 Turner et al. (2004) found that on average 34% of patients who received a 
stimulator experienced complications.  Delayed complications, such as lead migration, 
could occur any time and cause paresthesia in areas not associated with pain and lead to a 
lack of pain relief (Atkinson et al., 2011).  This validates the need for the systematic 
follow-up program that encompasses all patients with SCS implant with the incorporation 
of patient-orientated assessment methods that values the evaluation of treatment 
outcomes and detection of potential problems (Mannion, Junge, Fairbank, Dvorak, Grob, 
2006).  Follow-up questionnaires administered face to face or by phone in the first 6 and 
12 months and yearly are also critical for identifying problems related to the optimizing 
the use of the SCS implant for chronic pain management.  The QI project should also 
incorporate the special considerations related to the management of the SCS implant: 
reprogramming the device, the need for early detection of complications, and identifying 
the need for IPG replacement or repositioning. The SCS implant compatibility evaluation 
with cardiac pacemaker/defibrillators is critical for the success of both therapies. 
Magnetic resonance imagining (MRI) studies post-SCS implantation would be 
contraindicated because the magnetic field could produce lead migration or heating of the 
components (Atkinson et al., 2011). The secure database created by this project would 
provide the information about patients with SCS implant and help assure that appropriate 
interventions are provided for patients with SCS implant. 
Population identification 
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This QI project will be directed toward all patients who have placed and currently 
managed the SCS implant as a modality for chronic pain management in this medical 
center, which is part of VHA system in western part of U.S.  Both genders will be 
represented in the group, and all patients will be over 18 years old. The majority of the 
patient in the group have been diagnosed with FBSS and/or CRPS. The SCS implants 
that are currently managed come from one of three manufacturing companies: Boston 
Scientific, Medtronic, and St. Jude Medical.   
Settings 
           The primary settings for the development and implementation of this QI initiative 
took place in the Anesthesia Pain Clinic that is open five days per week and is staffed 
with an Anesthesiologist, a Certified Registered Nurse Anesthetist (CRNA), and a 
Registered Nurse (RN).  The Anesthesia Pain Clinic is an integrated part of the medical 
center and is located at close proximity to Same Day Surgery (SDS) unit. This allows for 
sharing financial and intellectual resources and creates continued collaboration toward 
the goal of proving the best possible care for veterans. 
Organizational Assessment and Assessment of Valuable Resources 
Anesthesia Pain Clinic Team. 
1. Anesthesiologist: identifies the need for the SCS implant as a treatment modality, 
places temporary/trial and percutaneous SCS implant, participates in 
determination of the suitability for a permanent SCS implant; and, after the 
permanent implant is placed, is involved in the reprogramming decisions, the 
replacement of the IPG, and maintenance of the SCS implant. 
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2. Certified Registered Nurse Anesthetist:  participates in the decision making of 
patient selection for the SCS implant, provides anesthesia delivery during the 
placement of the trial/percutaneous SCS implant, evaluates the outcomes of SCS 
modality, and involved with patient’s care during the follow up period.  
3. Registered Nurse: coordinates, monitors, and records information throughout the 
process, as well as communicates to members of Anesthesia Pain Clinic received 
from the telephone calls and nursing assessments. 
Neurosurgery Department. 
1.  Neurosurgeon:  selects candidates for the SCS implant, performs surgical 
placement of the permanent SCS implant, provides the 3 month postsurgical 
follow-up, and  does the removal and replacement of SCS implant system and 
IPG. 
2. Physician Assistant (PA):  participates in placement and provides follow-up after 
permanent SCS implant placement/removal and IPG exchange/removal. 
3. Registered Nurse: coordinates, monitors, and records information throughout the 
process, as well as communicates information received from the telephone calls 
and nursing assessment to members of Neurosurgery Department.  
Representatives/Equipment Consultants from the manufacturing companies 
        Representatives/Equipment Consultants from the manufacturing companies (Boston 
Scientific, Medtronic, and St. Jude Medical): provides SCS implants and responds to staff 
and patient questions and concerns about the device before and after implantation and are 
directly involved in reprogramming of SCS implants. 
 
Resources/Support 
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The financial resources for this QI project are incorporated into the budget of the 
Anesthesia Pain Clinic, along with support from the Office of Quality and Safety Systems 
of the medical center. The Neurosurgery Department, Same Day Surgery Department, the 
information technology (IT) team, and the manufacturing representatives from Boston 
Scientific, Medtronic, and St. Jude Medical are available to support this QI initiative. 
Anesthesia Pain Clinic Space: available as resource for this QI project (See Appendix A). 
Cost Benefit Analysis 
Taylor et al., (2010) used a decision-analytic model to examine the cost 
effectiveness of the SCS implant as compared to conventional medical management or 
reoperation. They incorporated in their analysis the frequency and cost of all 
complications in patients with SCS implant. The study supported previous findings 
(Kumar et al., 2006; North, et al., 2007) that despite the frequency of complications and 
their cost, the use of the SCS implant is more cost effective when compared to either 
conventional medical management or reoperation. This research data provides a solid 
basis for the cost effectiveness of this QI project, which creates a systematic follow-up of 
patient with SCS implant to improve this therapeutic modality’s efficacy and the quality 
of life for patient with chronic pain. 
Defining the Scope of this QI Initiative 
This QI initiative will incorporate the following elements: (a) the creation of a 
database for all patients with the SCS implants currently managed by the Anesthesia Pain 
Clinic within this VHA medical center located in west of U.S.; (b) the development of a 
questionnaire to collect information to guide the management of SCS implants and to 
evaluate the effectiveness of the modality at 6 and 12 month intervals followed by a 
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yearly follow ups; (c) the creation of a multidisciplinary team (Anesthesia Pain Clinic 
and Neurosurgery Department) with the integration of manufacturing representatives who 
will assist in providing timely and effective reprogramming of the SCS device; and (d) 
the maintenance of a physical space where the reprogramming of the device will occur 
along with arranging and managing appointments within the  Anesthesia Pain Clinic. 
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CHAPTER 3 
 CONCEPTUAL MODELS FOR THE PROJECT THAT SUPPORT THE VHA 
MISSION AND VISION 
             “The overarching goal of the Systems Redesign Sub-Initiative is to improve the 
VHA’s health care delivery systems operation to achieve our mission of providing 
exceptional healthcare. Implementation of continuous improvement is one of the VA’s 
top priorities. This goal requires each employee to engage in improving our work by 
creating increasingly reliable and timely systems responsive to patient needs.” 
(Department of Veteran Affairs, Office of Health Care Transformation, 2012, p. 19). 
Kotter’s Eight Step Model of Change provides a basis to initiate and implement the 
process of change within the organization and illustrates the need and urgency for change 
as well as helping facilitate those changes (Borkowski, 2009).  
Kotter’s Eight Step Model of Change has been used effectively to implement 
organizational changes; therefore, the steps identified in this model will be used to 
implement this project (Campbell, 2008).  Borkowski (2009) describes Kotter’s dynamic 
eight-step model for creating organizational changes, as follows:  
1. Establish the sense of urgency. The organization members examine current 
market and existing or potential crises and major opportunities that exist to create 
sense for urgency about the need for change. 
2. Create a powerful guiding coalition. The project manager should create powerful 
guiding coalitions that have the ability to enhance process and create changes at 
different levels of organization. 
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3. Develop a vision. The project manager should create a vision to direct the change 
effort and develop strategies to achieve that vision. 
4. Communicate the vision. The project manager should use all strategies possible to 
communicate the new vision and the approaches to achieve it. 
5. Empower others to act on the vision. The project manager should eliminate 
barriers to change and should encourage risk taking and creative problem solving. 
6. Plan for and create short-term wins. The project manager should plan for visual 
performance achievements and recognition of the team members who greatly 
contributing for the project. 
7. Consolidate improvements and produce more changes. The project manager 
should use the credibility achieved in short term wins to create more changes by 
reinvigorating the process with new projects, themes, and change agents. 
8. Institutionalize new approaches. The project manager should reinforce changes by 
focusing on the connections between new behavior and the success of the project 
and develop means for the leadership and further success of the project. 
 These steps create a culture for change by engaging and enabling team members 
and whole organizations to initiate changes and sustain changes (Campbell, 2008; 
Shirley, 2011).  As pointed by Campbell (2008), Kotter organizes each of these steps into 
three distinct phases: creating a climate for change, engaging and enabling the whole 
organization, and implementing and sustaining the change. 
The second contribution to the conceptual frameworks of developing and 
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implementing this QI initiative will be the VHA Quality Enhancement Research Initiative 
(QUERI). It was developed within VHA system between 1998 and 1999 to help facilitate 
QI initiatives (Feussner et al., 2000).   
In recent years, the VHA has used research to guide practice by the principles of 
evidence-based medicine, implementation of clinical practice guidelines, reduction of 
unnecessary practice variations, and improvement of clinical information management 
systems (Feussner, Kizer, & Demakis, 2000). The VHA QUERI focuses on translating 
research into clinical practice to improve patient outcomes at the systems level. Therefore 
the VHA QUERI brings additional epidemiological, economic, and statistical expertise to 
VHA QI programs by increasing interactions among researchers, clinicians, management, 
and others involved in quality assessment and improvement (Feussner et al., 2000; 
Hayward, Hofer, Kerr, & Krein, 2004).  The QUERI process is a 5-step approach in 
creating and implementing QI initiatives (Hayward, et al., 2004): 
1. Identify best practices 
2. Define existing practice patterns and outcomes 
3. Identify and implement interventions to improve practice 
4. Document that best practices improve outcomes 
5. Document that outcomes are associated with improved health-related quality of 
life 
  The QUERI consists of the logical overlap between this evidence-based practice 
basic principle of QI initiative and health services research (Feussner et al., 2000).  
Considering the five principles outlined above, the QUERI process will help guide the 
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implementation of this QI initiative designed for the systematic follow-up of the patient 
with SCS implant for chronic pain management.  
  The need for the development of a comprehensive follow up system for SCS 
implants has been demonstrated by research data (North, 2006; Atkinson et al., 2011) 
identifying and quantifying complications that can impede the efficacy of SCS implant; 
these complications can contribute to inadequate pain management (Taylor et al., 2010). 
The efforts to maintain or even improve efficacy of the SCS implant are aligned with the 
focus of QUERI and the quality of medical care that encompasses quality assurance and 
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CHAPTER 4 
DEVELOPMENT OF QI INITIATIVE OBJECTIVES 
 The objectives of this DNP based QI project are: (a) the creation of a database for 
all of the SCS implants currently managed by the Anesthesia Pain Clinic within medical 
center; (b) the development of a questionnaire to collect information to guide the 
management of SCS implants and to evaluate the effectiveness of the modality at 6 and 
12 month intervals followed by a yearly follow ups; (c) the creation of a multidisciplinary 
team (Pain Clinic and Neurosurgery) with the integration of manufacturing 
representatives who will assist in providing timely and effective reprogramming of the 
SCS device with the goal of achieving the best possible pain coverage for patients; and 
(d) the maintenance of a physical space where the reprogramming of the device will 
occur along with arranging and managing appointments within the Pain Clinic. 
The project will be developed and implemented at the VHA medical center located in 
western part of US, and will include all patients who have received the SCS implant for 
chronic pain management at this facility. The implementation of the project will be 
completed before December 31, 2012. 
Objective 1. 
The project will include the creation of a comprehensive database of all SCS 
implants placed and managed in this medical center.  The database will provide 
continuity of care and initiate systematic collection and evaluation of data related to SCS 
treatment to maximize the outcomes of SCS implant therapy. The database will also 
provide information for healthcare providers who want to add the pacer/defibrillator 
therapies and MRI studies for this patient population. 
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The database records the number patients who received the SCS implantation and 
identifies how many of those SCS implants are currently in use. It will not include 
patients who had their SCS implants extracted. The database has a multiple purposes: it 
provides easy assess to the number and identity of patients with SCS implant managed by 
this medical center. The names of the patients and identification data also are placed 
under Neurostimulation tab, which is directly linked to the CPRS Anesthesia-
Neuromodulation Note to provide detailed information about patient surgery and the 
current assessment of the SCS implant therapy.  
Objective 2.  
 Patient follow-up is a critical component for successful and safe use of SCS 
implants (Atkinson et al., 2011).  This project will develop a comprehensive follow-up 
questionnaire to evaluate pain coverage and detect possible complications in patients with 
SCS implant. The questionnaire is administered at 6 and 12 months after implantation, 
then at a yearly follow up.  A number of complications can develop and become 
exacerbated over time (Cameron et al., 2004).  Planned and timely follow up will help 
detect the onset of problems and can decrease or eliminate potential complications 
associated with the SCS implantation.  The information is saved in CPRS under 
Anesthesia Neuromodulation Note and will be available to all health care providers.  The 
Anesthesia Neuromodulation Note was developed as a template with the help of 
Information Technology Department after in approval by Title Committee.  
 The Anesthesia-Neuromodulation Note (see Appendix B) includes the following 
information: 
 Part I: Information obtained from CPRS 
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1. Disease process for which the SCS implant was intended. The information to 
complete this question was obtained from the CPRS Surgery Notes on the day of 
device placement. 
2. Date of the device placement and type of the device including time of the last 
remodulation provided to improve pain coverage. 
Part II: Information obtained in face-to-face conversation or by telephone: 
1. What is your pain intensity using Visual Analog Scale? 
The Visual Analog Scale (VAS) is the most commonly used measure of pain 
intensity in clinical and research settings.  Research supports the validity of this 
instrument to measure pain intensity (Ferreira-Valente et al., 2011).  The VAS is 
consistently used by the VHA system, and as a result, patients are familiar with its 
definition and application. 
2.   Is the quality of your life improved after the SCS implant placement? 
The literature reviews provide strong evidence that placement of SCS implant 
improve quality of life despite the relatively frequent issues with malfunctioning 
of the device and some inconsistency in pain coverage (North et al., 2006). 
3. Is there pain at the battery site? 
The review of the literature stated numerous problems at the battery site that 
require timely intervention (North et al., 2006). Battery position, fluid 
accumulation, and infection produce pain at the site. The earlier detection can 
decrease complications associated with SCS implant placement (Atkinson et al., 
2011). 
4. How mobile is the battery?  
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Addressing this question helps to determine if there danger that poorly anchored 
battery will pull on the leads, which increases risk of shifting and repositioning 
SCS implant (Atkinson et al., 2011). 
5. Are there any unusual changes around battery site? 
Swelling and redness are symptoms of approaching infection, and timely 
interventions provide the opportunity to diminish or stop its progression (North et 
al., 2006; Atkinson et al., 2011). 
6. Does the SCS implant sensation cover your pain? 
The sensation produced by SCS implant covering the painful area is the primary 
goal of this treatment modality, and it directly influences quality of life. 
7. How often do you utilize the SCS device?  
This question provides information about the usefulness of the device and 
satisfaction with this treatment modality. The questions also helps guide planning 
for IPG replacement if the device is constantly utilized. 
8. At what times did you find the SCS device not beneficial? 
The goal of this question was to pinpoint body position or situation where patients 
avoid using SCS implant or where the implant produced a painful stimulation. 
Additional Comments  
This part is designed for input of patient’s requests and recommendations for 
management of this modality. 
 The information collected by this questionnaire provides a wide range of data about the 
efficacy of this modality and is critical for further interventions to improve the efficacy 
and the longevity of spinal cord stimulator implants used for chronic pain management. 
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The questionnaire addresses patients concerns and requests about how the SCS implant 
will help guide clinical interventions to achieve better pain management as part of 
comprehensive care. 
Objective 3.  
          The multidisciplinary team includes members of the Anesthesia Pain Clinic and 
the Neurosurgery Department who work closely with the representatives from the 
manufacturing companies. The team members work together in the decision making 
process about device indication, implementation, programming, maintenance, and 
reprogramming/replacement. Collaborative, multidisciplinary teamwork is widely 
advocated as the goal of contemporary hospitals, but it is hard to achieve due to role 
boundaries and power, increased workloads, and a fragmented labor force (Plsek & 
Greenhalgh, 2001). Despite the challenges, collaboration among healthcare workers is a 
way to improve care delivery in an increasingly complex healthcare system (IOM, 2001) 
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Manufacturing Representatives/Equipment Consultants 
Figure 1. Schematic Approach for Creation of the Multidisciplinary Team and 
Representatives from the Manufacturing Companies 
  The creation of a multidisciplinary team will assure a comprehensive and 
effective follow up process with a focus on achieving the most effective pain coverage 
for patients with the SCS implant.  The manufacturer’s representatives are a critical part 
of the successful management of the SCS implant. They have the ability: to create 
programs that provide better pain coverage, evaluate and extend the longevity of IPG, 
and provide hands on education for patients about SCS implant reprogramming and 
management. The development of accurate and timely communication between all 
members of the multidisciplinary team is critical. Patient’s Responses from the 
questionnaire will guide the interventions that will be undertaken by the multidisciplinary 
team and manufacturer’s representative.  
Objective 4. 
 The permanent designation of a physical space to arrange and manage 
appointments within the Anesthesia Pain Clinic will be executed using resources 
available within Anesthesia Pain Clinic and by developing supporting relationship with 








   35 
Same Day Surgery (SDS) Department. SDS has an available Assessment Room every 
Monday and most afternoons. See Appendix D for the SDS Assessment room floor plan. 
The Associate Director of Quality and Safety Systems and the Manager of SDS support 
incorporating that space into this QI initiative. This additional area will be used for 
examination, evaluation, reprogramming of the device, and for patient education during 
the time when Anesthesia Pain Clinic space is not available. The Anesthesia Pain Clinic 
team is responsible for assuring that the team members are accessible to patients who 
need treatment. The Pain Clinic, with input from manufacturer’s representatives, will 
maintain the space and arrange scheduling to assure easy access for the patients. 
Risks/Threats to the Project 
 This QI initiative is solely developed for this VHA medical center incorporates 
specific characteristics of the patients with SCS implant who are treated at this center 
(large number of the patients with this particular treatment modality are managed by this 
medical center, and in some instances a very long traveling time to get the necessary 
intervention). The QI project is based on a research review, evidence-based data, and 
interviews with healthcare providers, patients, and manufacturing representatives. No 
similarly designed program was discovered in the literature review or in community 
practice. This made the QI program vulnerable to multiple threats during design and 
implementation phases and the long term establishment phase. The accurate and timely 
collection and input of the data about SCS implant modality is also concern, as contact 
with the patients can be inconsistent due to specific characteristics of the veterans 
population (high rate of homelessness, decreased financial resources, and high rate of 
posttraumatic stress disorder and depression). Another threat for implementing this QI 
   36 
initiative is the amount of the time required for the creation and maintenance of the 
database and for implementing the system of regular follow-up interventions.  The length 
of the project and the magnitude of its interventions will require collaboration and effort 
from all members of the multidisciplinary team over an extended time period, and it is 
critical to keep the program going despite possible disinterest over time, availability 
barriers, or employee turnover/sickness.  
Marketing Plan 
The following steps are in the marketing plan for this QI initiative: 
1. Provide a presentation to the multidisciplinary team involved in this project. 
Provide information on the current research and evidence-based data about SCS 
implant use for chronic pain management and the importance of a creation of 
systemic follow up to maximize the efficacy of this modality. 
2. Communicate progress of this QI project to a multidisciplinary team and 
Associate Director of Quality & Safety System and seek their feedback on the 
progress and problems of the project. Implement the necessary changes to 
improve program.  
 3.  Seek input and create awareness about this QI program within this medical center     
and communicate its importance to representatives from manufacturing 
companies. Gather commitments from manufacturing company representatives to 
be available at the Anesthesia Pain Clinic site to provide reprogramming and 
additional teaching for maintenance of the SCS implant if needed.  
Financial Plan 
          The budget for the creation and incorporation of this QI initiative was incorporated 
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into the budget of Anesthesia Pain Clinic. The community equivalent costs of creating 
and incorporating similar projects was analyzed to present the appropriate cost of this 
project. The cost of the project include employees’ pay, cost for the lease of office space, 
utilities, technical support, and the cost of the maintenance of a physical space where 
appointments will be provided. The weekly cost and total cost for the project 
implementation/maintenance are estimated using data from other institutions residing in 
the same area. Labor costs were broken down by basic pay per hour and included 
employee benefits. The specific data about costs related to this medical center will not be 
released. The yearly total cost is approximately $53,404 for the maintenance of the 
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Table 1 
QI Initiative Estimated Cost Based on the Local Area 
Services/Expenses Numbers Hours per 
Week 
Cost per Week 
Labor costs, including benefits, for 1 
physician:  
$110.00 per hour 
2 hour per week $220.00 
Labor costs, including benefits, for 1 
CRNA: 
$65.00 per hour 
2 hours per week $130.00 
Labor costs, including benefits, for 1 RN:  
$32.00 per hour 
1 hour per week $32.00 
Cost of software/programs to create and 
maintain the database: 
$50.00 per hour 
2 hours per week $100.00 
Costs for the maintenance of the physical      
space including equipment: 
$300.00 per hour 
1 hour per week $400.00 
Cost for the use of equipment:  
$60.00 per hour 
2 hours per week, along 
with the cost of 
software/programs to 
create and maintain the 
database 
$120.00 
Cost of the phone services: 
$20.00 per week 
1 hour per week $20.00  
Cost of office material: 
$5.00 per week 
1 time per week $ 5.00  
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Mentor/Site Arrangements 
 The project was developed as part of the Anesthesia Pain Clinic at VHA medical 
center. The project is designed to treat veterans afflicted with chronic pain.  The 
Department Head of the Anesthesia Pain Clinic is the primary mentor for the project and 
will supervise/evaluate the steps of the project as it progresses. 
Timeline and IRB Approval 
The quality improvement (QI) project of creating systematic follow–up for 
patients with spinal cord stimulator (SCS) implants was initiated in November 2012 and 
completed in December 2012. The project included patients who had the SCS implant 
placed or managed by a specific medical center, which is located in the western part of 
the U.S. and is part of the VHA system. The Neurostimulators List or database gathered 
for this study included all patients with the SCS implant placed between June 30, 2007 
and December 31, 2012 to reflect accurate information about the number of patients with 
SCS implants who been managed by this medical center. The follow-up questionnaire 
was administered to patients who had the SCS implant placed for chronic pain 
management before to October 2012, which allowed for at least one reprogramming to be 
completed after device insertion. The follow-up evaluation was completed using a 
questionnaire that was approved by the University of Nevada, Las Vegas, (UNLV) for a 
capstone proposal presentation. The questionnaire was reviewed and approved by the 
Anesthesia Pain Clinic and Neurosurgery Department of the medical center and was 
reviewed and approved as part of the Anesthesia-Neuromodulation Note by the Title 
Committee of this medical center. The Anesthesia-Neuromodulation Note is a permanent 
part of the CPRS within this medical center. 
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        Exempt status for this QI project was attained by working directly with the 
Institutional Review Board (IRB) and with the Associate Director of Quality & Safety 
Systems within this medical center. The VHA Operations Handbook 1058.05 stated that 
since this project is solely for the quality purposes, it should thus be initiated and 
implemented without IRB review. The UNLV IRB on November 16, 2012, deemed that 
this QI project was exempt from review. This QI project was structured as a process that 
occurred during and after scheduled working hours to provide the maximum probability 
of reaching/contacting all patients with SCS implants who are currently managed by this 











   41 
CHAPTER 5 
 SUMMARY OF IMPLEMENTATION AND RESULTS 
SCS Implant Database Development 
Multiple steps were undertaken to create a database of all SCS implants managed 
within this medical center. The initial information was retrieved from SCS logbooks, 
which provided only partial information about the number of the patients who had the 
SCS implant placed by this medical center. To obtain additional accurate data, the 
following sources of information were analyzed: (a) the Neurosurgery Department 
electronic surgical record, (b) the Anesthesia Pain Clinic electronic surgical record, and 
(c) the electronic referrals to Neurosurgery and Anesthesia Pain Department. The data 
from all of those sources was reviewed and compared to a prior list of patients to ensure 
that all patients with SCS implants were included in the database. Those steps initiated a 
new, on-going process: physicians from Anesthesia Pain Clinic will update the 
Neurostimulators List bi-weekly, adding the patient’s name after an SCS implant been 
placed.  
Presently, the Neurostimulators List includes 92 patients, of whom 80 were able 
to answer the follow-up questionnaire. Of the 12 patients who were not able to complete 
the questionnaire, one was unable to answer questions due to his mental status, 2 of the 
patients declined to participate, and 9 patients could not be reached despite multiple 
attempts to contact them. This Neurostimulators List includes all patients with SCS 
implants managed by this medical center, but it excludes patients who had SCS implants 
that were later removed for various reasons.  
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Development and Implementation of a Questionnaire for Follow-up about SCS Efficacy 
The SCS efficacy questionnaire was developed for the purpose of a creating a 
systematic follow-up assessment about the effectiveness of SCS implants and to guide the 
management of this modality (Atkinson at al, 2011; Taylor, 2010). The SCS efficacy 
questionnaire is now part of the Anesthesia-Neuromodulation Note and is a permanent 
part of CPRS within the medical center in which this project took place. It is available to 
be used by all healthcare providers. The SCS follow-up questionnaire was developed 
based on the literature review, evidence-based practice, patient’s requests for the creation 
of this follow-up program, and on-site clinical practice assessment. In aggregate these 
evaluations highlighted the existing problems and potential improvements related to SCS 
implant placement and management. This information directed the design of the 
questionnaire to identify the areas of interventions need for successful management of 
this therapeutic modality.  
The SCS efficacy questionnaire was developed based on the literature review, 
evidence-based practice, patient’s requests for the creation of this follow-up program, and 
on-site clinical practice assessment. In aggregate these evaluations highlighted the 
existing problems and potential improvements related to SCS implant placement and 
management. This information directed the design of the questionnaire to identify the 
areas of interventions needed for successful management of this therapeutic modality. 
The SCS efficacy questionnaire was presented and approved as part of the 
capstone proposal at UNLV in July 2012, following which it has been reviewed and 
accepted by the Neurosurgery and Anesthesia Pain Clinic Departments. The 
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questionnaire was also presented and approved by the VHA Title Committee and was 
placed by information technology department (IT) as an electronic template under title 
Anesthesia-Neuromodulation Note into CPRS records. The title for the note and the 
questionnaire template were consistently used for the follow-up telephone calls and face-
to-face assessments with SCS implanted patients. The Anesthesia-Neuromodulation Note 
is now a permanent part of the CPRS within the medical center and is available for the 6 
and 12-month follow-up assessments.  
 Creation of a Multidisciplinary Team for Management of Patients with SCS Implants 
The Anesthesia Pain Clinic staff (MD, CRNA, and RN), Neurosurgery staff 
(Neurosurgeon and PA, and RN), and manufacturing representatives (from St. Jude, 
Boston Scientific, and Medtronic) worked together to create a multidisciplinary approach 
for the managing patients with the SCS implant. This team effectively worked together to 
communicate data, receive feedback, and discuss SCS implants management to deliver 
timely and appropriate patient interventions.   
The CRNA initiate the follow-up process to evaluate the effectiveness of the SCS 
implant and the patient’s needs in managing the device in order to determine necessary 
interventions to improve patient outcomes. The follow-up information was recorded in 
CPRS and the patient’s name was added to the Neurostimulators List. This information 
was electronically forwarded along with the patient’s requests/comments to the 
Anesthesia Pain Clinic physician, so that the team could reference the information for 
current and future interventions. 
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The follow-up interventions are incorporated into a treatment plan following 
predetermined approaches that required close, timely communication among members of 
multidisciplinary team. The follow-up interventions fall into five categories: 
            1. The patient is satisfied with this treatment modality, and the SCS implant is 
functioning well and no interventions were needed. A total 33 patients, or 41.25% of all 
patients assessed, have satisfactory pain coverage and no problems with management of 
the SCS implant. No interventions were requested or required. 
             2. The follow-up questionnaire revealed that paresthesia sensation from the SCS 
implant was not covering the painful area and the reprogramming of SCS implant was 
needed. This information would be forwarded to Anesthesia Pain Clinic physician, who 
would initiate contact with one of the three manufacturing representatives (St. Jude, 
Boston Scientific, or Medtronic) to inform the representative about the patient’s 
reprogramming needs and facilitate a meeting at the medical center for an evaluation of 
the SCS implant programming, placement, and function. The reprogramming evaluation 
would take place at the Anesthesia Pain Clinic or in the Same Day Surgery Assessment 
Room to accommodate the flow of the patients and the effective and efficient use of time 
and space. The number of patients who requested or were offered on site 
evaluation/reprogramming was 27 patients, or 33.75%, and all of them have since their 
SCS implant reprogrammed. 
3. The follow-up requires surgical intervention, including: (a) battery 
replacement/repositioning (completed by Anesthesia Pain Clinic or Neurosurgery); or (b) 
SCS implant system removal/replacement (completed by Anesthesia Pain Clinic or 
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Neurosurgery). Those cases were evaluated on an individual basis, considering each 
patient’s physical status, preferences, and requirements for general anesthesia.  Either the 
Anesthesia Pain Clinic or Neurosurgery scheduled patients for surgery. The total number 
of patients who required and agreed to surgical interventions was 7, or 8.7% of all 
patients who had received the follow-up evaluation. All of them received or were 
scheduled for the necessary surgery. 
4. Information about follow-up interventions and care options available to address 
problems with SCS implants is communicated to the patient, but some patients chose not 
to proceed with any actions. Information about contact persons is offered to all patients 
along with an invitation to the patient to contact the Anesthesia Pain Clinic whenever 
they are ready to discuss issues at hand. The Anesthesia Pain Clinic physician is informed 
about all SCS implant management issues and patient’s desires not to proceed with any 
interventions. The total number of the patients who are aware of but choose not to 
address malfunctioning/non-functional SCS implant is 6, or 7.5% of the total patients 
evaluated.  
5. In some cases, the SCS implant has been reprogrammed a number of times and 
the patient feels that it is at its maximum performance, but they requested additional 
procedure for chronic pain management, such as trigger points injections, epidural steroid 
injections (ESI), selective nerve root blocks (SNRB), or radio frequency ablations (RFA) 
to augment the effect of SCS implant therapy. At this point Anesthesia Pain Clinic 
physician would initiate an order for the procedure, schedule the procedure, and follow 
the appropriate steps designed to assure the patient’s access to the Anesthesia Pain Clinic 
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and the desired procedure. The total number of the patients who requested additional 
procedures was 7, or 8.75%. 
Results Analysis 
 Participants and sample. Eighty patients with SCS implants answered the 
questionnaire. Of these, 65 (81.3%) had had the SCS implant for 3 years or less while the 
remaining 15 (18.8%) had the implant for more than 3 years. Due to the nature of the 
instrument and the context of the data collection process, no demographic information 
was collected from the sample except information related to gender. Sample included 4 
female or 5 % of total sample size of patients who participated by answering items in the 
questionnaire. 
Materials and Instruments 
  A researcher-developed a questionnaire was used to collect relevant data from the 
sample regarding various aspects of their SCS implant. The nine-item instrument 
included a combination of variables that were categorical/qualitative and 
continuous/quantitative. Items included information about patients’ previous 
remodulation date, their perceived pain using the VAS, perceived quality of life, and 
outcomes of their SCS implant treatment. With respect to perceptions of pain using the 
VAS, participants’ reported pain ranged from 0-10 (M = 5.45, SD = 2.42). Appendix C 
includes a full list of items on the instrument. Due to the nature of the items on the 
instrument, no composite—that is, overall score—was computed, as would be done on 
measures with true continuous interval or ratio scales, pseudo-continuous, or ordinal 
Likert scale items. Therefore, each item was analyzed separately. Also, because the items 
on the instrument were not unidimensional, no internal consistency reliability or 
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validation procedures were conducted on the data. The descriptive information of the 
items on the instrument provided in Appendix C. The descriptive information (frequency 
and proportions) of the items provided in Appendix D. 
   
Data Preparation 
 
 All data were screened for univariate outliers using box plots (i.e., box-and-
whisker graphs) for the pseudo-continuous VAS item according to the procedures 
outlined by Tabachnick and Fidell (2007).  No outliers were detected. Furthermore, data 
for the VAS item were tested for univariate assumptions, including normality (skewness 
and kurtosis) and homogeneity of error variance with respect to the outcome in order to 
proceed with data analysis. The data approximated a normal distribution at the univariate 
level, with kurtosis and skewness values for perceived pain ranging from -.09 to -.23, 
both >  (Tabachnick & Fidell, 2007), which is ideal. Therefore, data transformation 
procedures were not performed.  All other assumptions were also met, and thus, data 
analysis proceeded without any statistical adjustments to the data. 
Data analysis 
 A series of one-way analyses of variance (ANOVAs) was conducted to ascertain 
whether there were differences among key independent variables (i.e., remodulation time, 
quality of life, and utilization of SCS device), with perceived pain scores serving as the 
dependent variable in each analysis. Because the interpretation of effect sizes, or the 
strength/magnitude of the association between independent and dependent variables, 
YDULHVLWLVLPSRUWDQWWRHVWDEOLVKVRPHJXLGHOLQHV&RKHQVXJJHVWHGWKDWIRUȘ2 the 
following guidelines be used for interpreting the practical significance of results: .01 to 
PRGHVWWRPRGHUDWHDQGVWURQJ7he Bonferroni adjustment was 
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made to obviate Type I error rate inflation, which occurs when conducting multiple 
analyses (.05/3 = .02). This adjustment is necessary to prevent capitalizing on chance 
variance—that is, detecting differences when none exist.     
Results 
 In the first analysis, remodulation time (< 6 months, 6-12 months, > 12 months) 
served as the independent variable. Results of the one-way ANOVA indicated that the 
difference in patients’ perceptions pain was statistically significantly different as a 
function of remodulation time, F(2,78) = 2.09, p  Ș2 = .04, suggesting a modest strength 
of association between remodulation time and patients’ perceived pain. Post hoc 
comparisons using the Bonferroni adjustment for familywise Type I error rate inflation 
showed that patients who reported a remodulation time of less than 6 months (M = 4.97, 
SD = 2.35) reported significantly less pain than patients who reported a remodulation 
time between 6-12 months (M = 5.65, SD = 2.16) and more than 12 months (M = 5.86, 
SD = 2.66). The pairwise comparison between patients who reported remodulation time 
between 6-12 months and more than 12 months was not significant, p > .05. Thus, the 
greater the time since remodulation, the more pain patients reported.   
 Results of the one-way ANOVA with perceived improvements to quality of life 
due to the SCS device as an independent variable (none, somewhat, significantly) 
demonstrated that there were statistically significant differences between patients’ 
perceptions of pain, F(2,77) = 10.05, p Ș2 = .21. The post hoc follow up analyses 
demonstrated that there were significant (p < .01) differences between patients who 
reported significant improvements to their quality of life due to the SCS device (M = 
4.63, SD = 2.11) and those who reported no improvement to their quality of life (M = 
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7.44, SD = 2.19), with those who reported significant improvement reporting less 
perceived pain. The difference in perceived pain between those who reported some 
improvement (M = 5.78, SD = 2.37) and no improvement as well as those who reported 
significant improvement were not significant, all p-values > .08. 
 The one-way ANOVA with utilization of the SCS device (not at all, daytime only, 
nighttime only, day and night) serving as the independent variable showed that 
differences in utilization significantly influenced perceived pain, F(3,76) = 3.39, p Ș2 = 
.07. Post hoc analyses indicated that patients who did not utilize the SCS device reported 
significantly higher perceptions of pain (M = 6.47, SD = 1.85) than patients who utilized 
the device during the day (M = 4.27, SD = 1.79) and during the day and night (M = 5.33, 
SD = 2.63). Moreover, those who utilized the SCS device during the day reported 
significantly less pain than those who used the device at night (M = 5.50, SD = 3.00). 
Although none of the other pairwise comparisons reached statistical significance (all p-
values were > .05), it is interesting to note that those who utilized the SCS device during 
the day only reported significantly less pain than those who utilized the device during the 
day and night.   
  Table 2 contains the correlation coefficients between several key variables. 
  Because the variables under consideration were continuous and categorical, 
nonparametric correlation coefficients (Kendall’s Ĳb) were requested and interpreted in 
lieu of parametric coefficients (Pearson’s r). Nonparametric correlations, nevertheless, 
have the same interpretation as their parametric counterpart, Pearson’s r. All correlations 
were within normal bounds, ranging from -.07 to .65. Interestingly, the correlations 
between remodulation time and all other variables were not statistically significant, 
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suggesting that there is no association between remodulation time and any other variable.  
 Interpretation of statistically significant correlations follows. The modest inverse 
correlation between perceived pain and quality of life suggests that as improvements to 
quality of life due to the SCS device increase, perceived pain decreases. Likewise, the 
modest inverse correlation between SCS device pain coverage and perceived pain 
indicates that as reported pain coverage increases, perceived pain decreases. The modest 
inverse relation between outcomes and quality of life indicates that patients who required 
no reprogramming (coded as “0”) of their SCS device reported significantly greater 
improvements to their quality of life (“significant improvement” coded as “2”) due to the 
SCS device. The moderate, inverse correlation between outcomes and SCS device pain 
coverage suggests that patients who required no reprogramming of their SCS device 
tended to report greater pain coverage of their SCS device (coded as “2”). Finally, the 
strong, positive correlation between quality of life and SCS device pain coverage 
suggests that patients who reported greater pain coverage tended to report greater 













Variable  1 2 3 4 5 
 
1. Remodulation Time  - .14 ns .15 ns -.14 ns -.07 ns 
2. Perceived Pain (VAS)  - .13 ns -.36* -.35* 
3. Outcomes   - -.39* -.52* 
4. Quality of Life    - .65* 
5. SCS Device Pain Coverage     - 
* p < .01 (one-tailed)  ns = not significant  
N = 80    
    
An ANOVA was also conducted to ascertain whether time with the SCS device 
had an effect of patients’ perceived pain. Time with SCS device (less than 3 years, 3 
years or more) served as the independent variable and VAS pain score served as the 
dependent variable. Results showed that time did not significantly influence perceived 
pain, F(1,78)  S Ș2 = .03. Although not statistically significant, those with 3 or 
more years with the SCS device reported higher pain (M = 6.27, SD = 2.52) than those 
with less than 3 years (M = 5.26, SD = 2.38), suggesting that greater time with the device 
yields greater reported pain by patients.   
Designation of a Space for Follow-up for Patients with SCS Implant 
The objective of designating a physical space to arrange and manage appointments was 
achieved by a series of steps. Anesthesia Pain Clinic space (available all the time) and 
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SDS Assessment Room (available every Monday) were approved for remodulation of 
SCS implant and for additional consultations with multidisciplinary team. The 
manufacturing representatives coordinate patients’ time preferences and availability of 
that space. The Anesthesia Pain Clinic MD receives a follow-up note indicating the need 
for the reprogramming/reevaluation of an SCS implant and forwards the information to 
manufacturing representative the same day with time availability of all multidisciplinary 
team members required for the patient’s specific condition. The Anesthesia Pain Clinic 
physician contacts the appropriate manufacturing representative to discuss the specifics 
of that patient’s condition, device placement, and expectations of the therapy. The time 
and place for reprogramming/evaluation are initiated by the manufacturing 
representatives in Same Day Surgery (SDS) or in the Anesthesia Pain Clinic Site, 
depending on site availability and the preferences of the involved parties. If any 
additional assessment is needed, the Anesthesia Pain Clinic physician is available onsite, 
so assessment and discussion about surgical intervention and referral and scheduling to 
Neurosurgery are made at that time. If necessary all members of the multidisciplinary 
team can be involved in discussions about further interventions and management of the 
SCS implant during patient visit. The availability of X-ray at the Anesthesia Pain Clinic 
provide an opportunity to quickly ascertain the position of SCS implant, and if additional 
information was needed, a CT scan can be ordered on the site. 
Implementation of the QI Project Using Kotter’s Framework, Incorporating VHA 
QUIRE 
  This QI project was successfully implemented using Kotter’s Eight Step Model of 
Change (1995, 1996) for implementing organizational changes. The project also 
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incorporated VHA QUIRE, which focuses on translating research discovery into patient 
care and healthcare system improvements (Feussner et al., 2000). The first step in this 
model is to examine the criteria that create the increased urgency by evaluating potential 
situation or evaluating potential opportunities or needs.   
            Research revealed the urgency behind this issue by reporting complications and 
longevity limitations of the SCS implant treatment modality. Present clinical practice, 
record evaluation, and responses from providers and patients echo these issues.  The need 
for creation of this QI initiative was communicated to the Anesthesia Pain Clinic, 
Neurosurgery Department, and Associate Director of Quality and Safety System to create 
awareness of the need to create systematic follow-up for patients with SCS implants, in 
order to improve quality of patient care and be in compliance with the VHA initiative for 
systematic multidisciplinary follow-up for patient with chronic pain (VHA Directive 
2009-053, 2009). 
            Step two in Kotter’s model – build guiding teams – is necessary for the successful 
implementation of this project.  This is the creation of powerful guiding teams/coalitions 
from different levels of the organization (clinical and administrative), including members 
of the multidisciplinary teams.  Explicating the objectives of this project was critical 
because the multidisciplinary members provide care at different stages of treatment; 
therefore, it is important for all members to be informed about steps in the treatment and 
the patient’s progress. The presentation about current research data related to SCS 
implant complications and the potential benefits of implementing this QI initiative 
(ethical, health maintenance/improvement, financial) (North et al., 2004; Atkinson et al., 
2011) was presented to the Anesthesia Pain Clinic, Neurosurgery Department, and the 
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Associate Director of Quality and Safety Systems 
  The vision from the project came from developing a detailed plan for this QI 
initiative (step 3) and effectively communicating it (step 4) to all parties involved. 
Creating support for this (QI) initiative and offering of additional resources (SDS 
Assessment Room to be used as part of the clinical space) were vital steps that took place 
to consolidate organizational effort to create this QI program.  Encouraging problem 
solving behaviors and support for new initiatives is necessary to help decrease/illuminate 
barriers to change (Maxwell, 2009).  During this phase of the project (step 5, enable the 
action or empower other to act on the vision), the acceptance and support for this QI 
initiative prompted CRNAs to contact manufacturing representatives and re-negotiate the 
terms for the reprogramming of the SCS implant based on Anesthesia Pain Clinic 
requests and renegotiate more timely terms (within one week of request).  
  The creation of visible short-term wins (step 6), such as approval of the program, 
multi-organizational level support for the program, and positive patients and team 
members’ feedback created an environment of acceleration and pride for the needed 
patient care. This helped create critical stepping stones by securing small wins and 
preparing health care providers to embrace embracing larger changes (Maxwell, 2009).   
 The project was divided into subprojects, and at certain points different members 
of multidisciplinary team took more responsibility for specific part of the project (for 
example, the Pain Clinic physician insisted that all outcomes of reprogramming of SCS 
implant be reported directly to him by manufacturing representatives). The close contact 
with manufacturing representatives not only positively influence the time frame for 
reprogramming the SCS implant, but also encouraged the manufacturing representative 
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from St. Jude to offer a one hour education session to SCS implants candidates (step 7, 
reinvigorate the process with new project).  The reinforcement of newly created changes 
is critical (step 8); providing evidence and highlighting how these new behaviors and 
standards of clinical practice contribute to organizational success created support from all 
members of multidisciplinary and the organization as whole.  
This QI project was successfully guided and implemented by three distinct phases of 
implementing changes: creating a climate for change, engaging and enabling an 
organization, and implementing and sustaining change (Campbell, 2007). These steps are 
the essential structure of Kotter’s Eight Step Model of Change and are synchronized with 
steps of the QUERI which guided implementation of this QI project and contributed to 
improvement in quality of life for patient with SCS implant.  
Conclusion and Recommendations  
          The increasing use of SCS implants for chronic pain management; and the data 
analysis of this DNP QI initiative when viewed through the biopsychosocial lens, 
provides the opportunity to incorporate and evaluate additional elements of care. The 
unique characteristics of the VHA system, e.g., the use of CPRS and the volume of 
prescriptions written and filled within VHA system, offer opportunities to evaluate the 
use of  medication for chronic pain management and its cost, prior to and during the use 
of  the SCS implant treatment modality.  
  The use of SCS implants was demonstrated to be effective in some pain 
syndromes that were resistant to other treatments. It is well tolerated by patients, is 
minimally invasive and can be reversed. When compared to chronic pharmacotherapies, 
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SCS implants had fewer adverse effects.  Traditionally, pharmacotherapy had a central 
role in chronic pain management (Wolf, 2004).  The use of SCS implant provides the 
opportunity for patients and the treatment team to decrease the use of and potential for 
medication interactions or adverse effects (North, Shipley, & Taylor, 2009).  
  Further development of this QI initiative allows for the opportunity to evaluate 
and make changes in  healthcare consumption, e.g., ESI, cross-over for alternative 
treatments; and the use of pharmaceuticals as measured by reviewing medical records and 
incorporating the use of instruments, such as, the Medication Quantification Scale (North 
& Shipley, 2007). The complete elimination or significant reduction in pain would be the 
ideal outcome for patients with SCS implants. Incorporation of The Oswestry Disability 
Index (ODI) which is disease specific for low back pain; and the Pain Disability Index 
(PDI) within the DNP project questionnaire can provide additional information about 
patient abilities to engage in activities of daily living and various life activities.  
The ODI is the most commonly used, self-administered outcome-measure 
questionnaire for low back pain that assesses various activities of daily living (Mehra, 
Baker, Disney, & Pynsent, 2008). The ODI questionnaire takes 3.5-5 minutes to 
complete. It helps to measure outcomes of treatment and maintains standards of medical 
care. Integration of the ODI as part of the systematic follow-up of SCS implant patients 
would provide the additional patient-oriented assessment methods important in the 
evaluation of treatment outcomes (Mannion, Junge, Fairbank, Dvorak, & Grob, 2004).  
             The Pain Disability Index (PDI) was designed to measure the extent to which 
chronic pain interferes with a person’s ability to engage in various life activities. It 
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focuses on seven categories (Family/Home Responsibilities, Recreation, Social Activity, 
Occupation, Sexual Behavior, Self-Care and Life Support Activity). Patients are asked to 
rate their level of disability on graphic scales ranging from 0 (no disability) to 10 (total 
disability). The disability score is a summary of numerical ratings from all of these 
categories, ranging from 0 to 70 (Pollard, 1984). The PDI was used in multiple studies 
that evaluated the effectiveness of SCS implant for pain management (Bennett 
&Brookoff, 2006). It too can be a useful outcome measurement tool if added to the 
follow-up questionnaire used in this project. Finally, the development of patient-
orientated assessment methods is of paramount importance in the evaluation of treatment 
outcomes and for detecting potential problems (Mannion et al., 2006); these are critical 
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APPENDIX B: THE ANESTHESIA-NEUROMODULATION NOTE 
INCORPORATING THE QUESTIONNAIRE 
The Questions that will be administered to the patients, face to face, or by the phone. 
A. The disease process to which the device implementation has been indicated (data 
obtained from CPRS in the postsurgical note).  
B. The date of the device implementation, and the type of device, along with its 
placement, and the last remodulation date (data obtained from CPRS in the postsurgical 
note and patient). 
1. What is your pain intensity using Visual Analog Scale? 
0 to 10 (0- no pain, 5- moderate pain, 10- worst possible pain) 
2. Is the quality of your life improved after the SCS implant placement? 
a. No   b. Somewhat    c. Significantly  
3. Is there pain at the implanted battery site?  
a. No  b. Somewhat   c. Yes 
4. How mobile is the battery? 
a. Not at all b. Somewhat   c. Very mobile 
5.  Are there any unusual changes around the battery site? 
a. Yes               b. No  
6. Does the SCS implant sensation cover your pain? 
a. Not at all  b. Somewhat      c. Significantly  
   60 
7.  How often are you utilizing the SCS device?  
a. Not at all   b. Daytime only   c. Nighttime only   d. Day and night 
      8. At what times did you find the SCS device not beneficial? 
 
Additional Comments: Include information that describes specific details and the 
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APPENDIX D: DESCRIPTIVE INFORMATION OF THE ITEMS ON THE 
INSTRUMENT 
Variable                                    N† (%) 
 
Remodulation Time 
 < 6 months  32 (40.0) 
 6 to 12 months 20 (25.0) 
 > 12 months 28 (35.0) 
 
Quality of Life Improvement 
 None 16 (20.0) 
 Somewhat 18 (22.5) 
 Significantly 46 (57.5) 
 
Pain at Implanted Battery Site 
 None 61 (76.3) 
 Somewhat 13 (16.3) 
 Significant 6 (7.5) 
 
Mobility of the Battery 
 None 67 (83.8) 
 Somewhat 11 (13.8) 
 Very mobile 2 (2.5) 
 
Unusual Changes Around Battery Site 
 No 79 (98.8) 
 Yes 1 (1.2) 
 
Pain Coverage of SCS Implant 
 None 21 (26.3) 
 Somewhat 24 (30.0) 
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Frequency of Utilization of SCS Device 
 Not at all 15 (18.8) 
 Daytime only  11 (13.8) 
 Nighttime only  4 (5.0) 
 Day and night 50 (62.5) 
 
Perceived Lack of Benefit of SCS Device* 
 Extending/flexing 7 (8.8) 
      Lying down 2 (2.5) 
 Works all the time 7 (8.8) 
 
Interventions Provided to Patients 
 None 33 (41.3) 
 Device needed/reprogrammed 27 (33.8) 
 Surgical interventions addressed 7 (8.8) 
 Interventions addressed, patient not prepared 6 (7.5) 
 Pain Clinic provided procedures to augment 
      SCS implant function 7 (8.8) 
 
* The majority of patients (80%) did not answer this item.  
N = 80 
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This memorandum is notification that the project referenced above has been reviewed as 
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